🚀 VC round data is live in beta, check it out!
MARX Biotech Valuation Multiples
Discover revenue and EBITDA valuation multiples for MARX Biotech and similar public comparables like Jade Group, BlueMTec, 09Women, Kurashicom and more.
MARX Biotech Overview
About MARX Biotech
MARX Biotech Co Ltd is a retail company which has developed an O2O and OMO full-channel layout in the online Internet platform and cosmeceutical retail market, and has successfully established itself in the market and Build trust and operational growth on the channel side. It has has established more than three thousand large and small cosmeceutical pharmacies in Taiwan, including: Dashu Pharmacy, Dingding Pharmacy, Cosmed, Watsons, Spring Pharmacy, New Gaoqiao Pharmacy, Anlier Pharmacies, etc.
Founded
2021
HQ
Employees
N/A
Website
Financials (FY)
EV
$111M
MARX Biotech Financials
MARX Biotech reported last fiscal year revenue of $19M and negative EBITDA of ($2M).
In the same fiscal year, MARX Biotech generated $13M in gross profit, ($2M) in EBITDA losses, and had net loss of ($3M).
MARX Biotech P&L
In the most recent fiscal year, MARX Biotech reported revenue of $19M and EBITDA of ($2M).
MARX Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $19M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $13M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 70% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($2M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (13%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (13%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($3M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (16%) | XXX | XXX | XXX |
| Net Debt | — | — | $6M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
MARX Biotech Stock Performance
MARX Biotech has current market cap of $101M, and enterprise value of $111M.
Market Cap Evolution
MARX Biotech's stock price is $0.19.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $111M | $101M | 0.2% | XXX | XXX | XXX | $-0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMARX Biotech Valuation Multiples
MARX Biotech trades at 5.7x EV/Revenue multiple, and (46.0x) EV/EBITDA.
MARX Biotech Financial Valuation Multiples
As of March 19, 2026, MARX Biotech has market cap of $101M and EV of $111M.
Equity research analysts estimate MARX Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
MARX Biotech has a P/E ratio of (33.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $101M | XXX | $101M | XXX | XXX | XXX |
| EV (current) | $111M | XXX | $111M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 5.7x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (46.0x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (45.9x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 8.3x | XXX | XXX | XXX |
| P/E | — | XXX | (33.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (10.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified MARX Biotech Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
MARX Biotech Margins & Growth Rates
MARX Biotech's revenue in the last fiscal year grew by 113%.
MARX Biotech Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 113% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (13%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 634% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 66% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 12% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 82% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
MARX Biotech Public Comps
See public comps and valuation multiples for other Consumer E-commerce and Pharmacies comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Jade Group | XXX | XXX | XXX | XXX | XXX | XXX |
| BlueMTec | XXX | XXX | XXX | XXX | XXX | XXX |
| 09Women | XXX | XXX | XXX | XXX | XXX | XXX |
| Kurashicom | XXX | XXX | XXX | XXX | XXX | XXX |
| a.k.a. Brands | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
MARX Biotech M&A Activity
MARX Biotech acquired XXX companies to date.
Last acquisition by MARX Biotech was on XXXXXXXX, XXXXX. MARX Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by MARX Biotech
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMARX Biotech Investment Activity
MARX Biotech invested in XXX companies to date.
MARX Biotech made its latest investment on XXXXXXXX, XXXXX. MARX Biotech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by MARX Biotech
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout MARX Biotech
| When was MARX Biotech founded? | MARX Biotech was founded in 2021. |
| Where is MARX Biotech headquartered? | MARX Biotech is headquartered in Taiwan. |
| Is MARX Biotech publicly listed? | Yes, MARX Biotech is a public company listed on Taipei Exchange. |
| What is the stock symbol of MARX Biotech? | MARX Biotech trades under 7731 ticker. |
| When did MARX Biotech go public? | MARX Biotech went public in 2024. |
| Who are competitors of MARX Biotech? | MARX Biotech main competitors are Jade Group, BlueMTec, 09Women, Kurashicom. |
| What is the current market cap of MARX Biotech? | MARX Biotech's current market cap is $101M. |
| What is the current revenue of MARX Biotech? | MARX Biotech's last fiscal year revenue is $19M. |
| What is the current EV/Revenue multiple of MARX Biotech? | Current revenue multiple of MARX Biotech is 5.7x. |
| Is MARX Biotech profitable? | No, MARX Biotech is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.